Investor Ideas Potcasts, Cannabis News and Stocks on the Move; Episode 485 (TSXV: DB) (OTCQB: DBCCF), (CSE: XCX) (TSXV: NUMI)
Today's podcast sponsored by Cannabis Suisse Corp. (OTC: $CSUI), a fully licensed cannabis cultivation and distribution company in Switzerland
Delta, Kelowna, BC - October 22, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today's podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Investor Ideas Potcasts, Cannabis News and Stocks on the Move; Episode 485 (TSXV:DB) (OTCQB: DBCCF), (CSE: XCX) (TSXV: NUMI)
Today's podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
Today's podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's facilities for producing cannabis are based in Dietikon, Switzerland, and contain the art surveillance equipment to enable an around the clock webcast. Cannabis Suisse grows high quality, organic cannabis with sustainable, all-natural principles. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse proprietary trademarked MoldStandard is a quantitative microbiology method for analyzing yeast and mold counts in harvested cannabis plants. Cannabis Suisse proprietary trademarked CannaMec is a method for quantifying and removing residual solvents during packaging and storage of CBD products. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.
In today's podcast we look at a few public and private company announcements.
"Our product strategy is driven by our intimate knowledge of the end consumer through our Prairie Records retail stores," said Adam Coates, Chief Growth Officer of Decibel. "This position allows for insights such as identifying whitespace opportunities the current market is not fulfilling, and understanding key product attributes consumers are looking for in established formats. With these insights, we are launching black market quality concentrates, high potency, strain specific vapes and the CUE line of fast acting 10mg THC shot style beverages."
Product Launch Highlights
- 10 Product Skus Launched: Achieved its first 57 product sku registrations in Western Canada and a supply agreement with the Ontario Cannabis Retail Corporation, with 10 skus currently available in cannabis retail stores across British Columbia, Alberta and Saskatchewan. The first shipments of products were delivered in late Q3.
- Blendcraft by Qwest Concentrates: Decibel's first derivative product launches under the Blendcraft by Qwest banner with 4 skus of Wax (crumble) and 4 skus of Shatter. These high potency, in demand concentrates compliment the rare cultivar, craft dried flower products the Company produces under the Qwest Family of Brands.
- General Admission Vapes: Decibel has launched its new brand, General Admission, with four strain specific vapes (Berry G 33, Tropic GSC, Lemon Ice and Tropic Thunder) in 0.45g and 0.95g cartridges, and 0.3g disposable formats. With high potency THC dominant and THC/CBD balanced formulations and a strong value-for-price ratio, first shipments of these products have been successful with re-orders from initial product shipments achieved within the first week of launch.
- CUE Fast Acting Cannabis Shots: The Company has entered into a definitive agreement with Origin Scientific Inc., a private Canadian company, to manufacture and distribute CUE fast acting cannabis shots. CUE has developed an industry leading, clinically proven and patented nano encapsulation technology that has been formulated into a fast-acting cannabis infused shot style beverage. "CUE Lemon Tea", a 59ml cannabis shot with 10mg of THC and 30mg of naturally occurring caffeine is expected to be the initial product offering, which the Company anticipates to be available for sale in November.
AMP German Cannabis Group Inc. (CSE: XCX) providing German patients with a wide range of pharmaceutical grade medical cannabis products, announced it will be adding Little Green Pharma Ltd. (ASX: LGP) cannabis oil medicines to its catalogue for sale in Germany beginning in November 2020 subject to obtaining a BtM-registration (narcotic drug licence) of these products on behalf of AMP.
AMP is looking forward to offering premium EU-GMP full plant extract cannabis oil medicines branded under the LGP Classic brand, produced by the same consistent strains. AMP wants to introduce the LGP brand to the German market by selling "LGP Classic 20:5 Oils" (THC dominant) and additional products in the near term once AMP has established the brand in the German market. Whereas LGP`s full plant extracts originate from the same cannabis plants, many other cannabis extracts are sourced from varying cannabis plants.
Little Green Pharma is licenced to cultivate and produce medical cannabis in Australia and has obtained the required licences and permits to export to Germany. Little Green Pharma has its own Therapeutic Goods Administration ("TGA") GMP licensed manufacturing facility in addition to a six-year, exclusive manufacturing agreement with a third-party TGA-GMP licensed contract manufacturer based in Western Australia. The TGA-GMP certification, granted by Australia's Department of Health, is recognized by EU regulatory authorities as meeting EU-GMP standards enabling LGP products to be sold in Germany.
Dr. Stefan Feuerstein, Director and President of AMP, said: "We had a lot of requests for medical cannabis oils during our recent sales trip through Germany, where we met with medium-sized distributors and large pharmacists that are specializing in medical cannabis. To meet this demand, we are introducing the premium LGP Classic brand as our first extract brand for the German market. We wanted our first extract in our product line to be a premium, full plant extract that our sales team can introduce along with our other medical cannabis flower products. We will be adding additional cannabis oils in the coming months to satisfy our customers' strong demand for this product line."
Ms. Fleta Solomon, Managing Director of Little Green Pharma, commented, "Our focus is on producing the highest quality cannabis medicines for Australia and other countries where medicinal cannabis has been legalized. We are proud to be the first Australian company to supply Germany, the leading medicinal cannabis market in Europe, and that AMP will be introducing the LGP Classic brand. We expect strong sales from AMP as they immediately launch and invest in introducing our LGP Classic 20:5 oil to the German market and additional LGP Classic products in the near term."
Numinus Wellness Inc. (TSXV: NUMI), a company creating an ecosystem of health solutions centred on developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, announced that they have harvested the first legal flush of Psilocybe mushrooms in Canada by a public company under its Health Canada-issued Controlled Drugs and Substances Dealer's Licence. This news coincides with other recent developments by Numinus Bioscience, the Company's 7,000 square foot analytics and research laboratory, which is focused on handling various psychedelic substances and developing analytical methods and formulations for the evolving psychedelics space.
"The first harvest of legally grown Psilocybe mushrooms is a significant milestone for the whole industry" said Michael Tan, Chief Operating Officer. "Now, we can progress with research and development of standardized cultivation, extraction, and testing methods and exploring product formulations to support safe, evidence-based, accessible psychedelic-assisted psychotherapy, as well as build a sequenced spore library."
Dennis McKenna, renowned ethnopharmacologist, Co-founder of the Heffter Research Institute, Founder of the McKenna Academy of Natural Philosophy, and member of Numinus' General Advisory Council, adds, "While there is a place for synthetic psilocybin in clinical practice, well-characterized and standardized extracts of natural forms of psilocybin i.e., mushrooms, cultivated and processed under stringent quality control protocols, are the wave of the future as therapeutic psilocybin gains acceptance. Given a choice, many people would prefer the option to use natural psilocybin. Mushrooms have been used in traditional medicine for literally thousands of years, and hence, they are just that much closer to these ancient traditions. Natural mushroom extracts are also likely to be far more affordable compared to synthetic psilocybin, and that is an important consideration when it comes to ensuring accessibility to this medicine which can be so beneficial to many people. Cost should not be a barrier to access these medicines, and the use of mushroom extracts will help ensure those who need them most can benefit from psilocybin therapies."
Numinus Bioscience is establishing itself at the forefront of analytical testing for psychedelic substances, as a centre of excellence for psychedelic product research and development, and as an ancillary for psychedelic therapy clinical trials. Health Canada licences, scientific expertise, and state-of-the-art technologies facilitate ongoing innovation, while revenue from high-throughput contract cannabis testing is reinvested to further its psychedelic initiatives.
In addition to today's announcement, Numinus includes in its recent developments an amendment application to its Health Canada-issued Controlled Drugs and Substances Licence. The current licence permits testing, import and export, storage and distribution of MDMA, Psilocybin, Psilocin, DMT, and Mescaline as well as the undertaking of novel mycological research initiatives. The amendment will additionally permit the sale of Psilocybe mushroom fruiting bodies and extract for clinical research protocols and the development of standardized testing for additional psychedelic substances.
Numinus is also proud to announce the recent appointment of Sharan Sidhu, regulatory expert and policy advisor for restrictive high growth industries, as Science Officer and General Manager. Sidhu brings extensive experience as a hub between academia, industry, and governing directorates to align research objectives with regulatory compliance. She has been a key strategist for research roadmaps, core initiatives, the development of IP, and the development of compliance requirements including LIMS, GLP/GMP, GACP, and ISO Standards.
"Sharan's experience and leadership are already proving instrumental in establishing Numinus Bioscience as a centre of excellence and major industry player in the delivery of safe, evidence-based, accessible psychedelic-psychotherapy," said Payton Nyquvest, CEO, Founder, and Chairman. "We are honoured to have her join us on our mission."
Once again, today's podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining the AI Eye.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
Disclosure: Cannabis Suisse Corp. (OTC: CSUI),is a paid featured company on Investorideas.com
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Cannabis Social Media
Download our Mobile App for iPhone and Android